BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32867461)

  • 21. Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non-surgical esophageal squamous cell carcinoma patients treated with radiotherapy.
    Zhi X; Jiang K; Shen Y; Su X; Wang K; Ma Y; Zhou L
    J Clin Lab Anal; 2020 Oct; 34(10):e23468. PubMed ID: 32681567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.
    Lertbutsayanukul C; Tharavej C; Klaikeaw N; Prayongrat A; Lowanitchai C; Sriuranpong V
    Thorac Cancer; 2017 May; 8(3):219-228. PubMed ID: 28322515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of postoperative radiochemotherapy for thoracic esophageal squamous cell carcinoma with lymph node metastasis].
    Lin Y; Chen J; Li J; Liu J; Zhu K; Pan C; Chen M; Pan J
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):151-4. PubMed ID: 24796467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.
    Mou Y; Liang P; Cheng X; He X; Zhang J; Liu L; Liu Q
    BMC Cancer; 2024 May; 24(1):646. PubMed ID: 38802765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
    Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
    Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
    Li C; Wang X; Wang X; Han C; Wang P; Pang Q; Chen J; Sun X; Wang L; Zhang W; Lin Y; Ge X; Zhou Z; Ni W; Chang X; Liang J; Deng L; Wang W; Zhao Y; Xiao Z
    BMC Cancer; 2019 Apr; 19(1):397. PubMed ID: 31036088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
    Dreyfuss AD; Barsky AR; Wileyto EP; Eads JR; Kucharczuk JC; Williams NN; Karasic TB; Metz JM; Ben-Josef E; Plastaras JP; Wojcieszynski AP
    Cancer Med; 2021 Feb; 10(4):1275-1288. PubMed ID: 33474812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
    Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of chemoradiotherapy using intensity-modulated radiation therapy for cervical esophageal cancer: a single institute experience.
    Inada M; Nishimura Y; Ishikawa K; Uehara T; Wada Y; Oguma Y; Doi H; Nakamatsu K
    Esophagus; 2021 Jul; 18(3):638-644. PubMed ID: 33417068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
    Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
    Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
    Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
    Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
    Xu X; Wang Z; Jiang S; Shang Y; Wu Y
    Radiat Oncol; 2019 Nov; 14(1):191. PubMed ID: 31684983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience.
    Hamer PW; Hight SC; Ward IG; Harris DL; Woodham BL; Flint RS
    ANZ J Surg; 2019 Apr; 89(4):367-371. PubMed ID: 30791194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
    Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
    Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
    Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.